Corsair Pharma, a Sunnyvale, CA-based private biopharmaceutical company developing a transdermal treprostinil prodrug, raised $23M in Series B funding.
The round was led by New Rhein Healthcare Investors, with participation from Junson Capital, Primavera Capital, Plaisance Capital and Midas Capital.
Led by Bobby Singh, Ph.D., President, CEO and Director, Corsair Pharma is developing solutions to improve the therapeutic profile of medications and provides treatment options for patients. The company is focused on the development of prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch. The patch is intended to provide continuous and consistent blood levels of the drug Treprostinil comparable to an infusion pump. It delivers an inactive prodrug of treprostinil, which is intended to cross the skin, enter the blood, and convert rapidly to treprostinil in the liver.
The company intends to use the funds for the clinical advancement of its patch.
FinSMEs
21/09/2023